LUCIDITY delivers the first randomized double-blind placebo-controlled Phase 3 success for post-bariatric hypoglycaemia, with once-daily subcutaneous avexitide cutting the composite rate of self-monitoring-confirmed Level 2 and adjudicated Level 3 events by 55% over 16 weeks in 78 Roux-en-Y gastric bypass adults, including 63% fewer Level 2 and 47% fewer Level 3 events. The result gains credibility from mechanistic coherence across four direct GLP-1 receptor antagonist peers: PREVENT in 18 women raised glucose nadir 21% to 26% and lowered insulin peak 21% to 23%, the Phase 2b crossover in 16 completers cut diurnal Level 2 events 47.7% to 59.0% and Level 3 events 66.1% to 67.5%, Stanford multiple-ascending-dose work in 19 women raised nadir 47% with 67% lower peak insulin, and intravenous Exendin (9-39) in 8 participants normalized nadir and cut insulin AUC 57%. [1][2] Competitive context is thin and early: pasireotide Phase 2 at 72 patients and sotagliflozin ONSIDE at 24 patients remain ongoing without results, while XOMA 358 at 20 patients and mizagliflozin at 9 patients are small Phase 2 signals. [3][4] No closely comparable precedent exists for a GLP-1 receptor antagonist in this population, with no prior approval, rejection or HTA decision to anchor pathway, pricing or label. [1] Payer leverage rests on severe-event avoidance plus prior 90 mg daily gains in HFS-II and EQ-5D-5L, but safety, hyperglycemia risk, dropout handling and durability beyond 16 weeks remain undisclosed, leaving a modest single-trial base for chronic use. [1]
78-patient 16-week Phase 3 RCT met composite and Level 2/Level 3 endpoints, but first-in-class status with small short prior base and undisclosed safety limits confidence.
| Indication | Post-bariatric hypoglycaemia |
| Drug | Avexitide |
| Mechanism of Action | GLP-1 receptor antagonist |
| Company | Amylyx Pharmaceuticals |
| Trial Phase | Phase III |
| Trial Acronym | LUCIDITY |
| NCT ID | NCT06747468 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Patient Population | 78 adult patients with PBH following Roux-en-Y gastric bypass (RYGB) surgery |
| Study Design | Randomized, double-blind, multicentre, placebo-controlled |
| Primary Endpoint Result | 55% reduction in composite rate of Level 2 and Level 3 hypoglycaemic events |
| Avexitide LS Mean Event Rate | 0.55 events per week |
| Placebo LS Mean Event Rate | 1.24 events per week |
| Secondary Endpoint Reductions | Level 2 events by 63%, Level 3 events by 47%, CGM-detected Level 2 events by 42% |
| Regulatory Designations | Breakthrough Therapy Designation, Orphan Drug Designation |
| Regulatory Agency | US Food and Drug Administration (FDA) |
| Acquisition Value | $35m |
| Administration Route | Subcutaneous |
Amylyx's Avexitide Achieves Significant Hypoglycemia Reduction in Phase III LUCIDITY Trial
Amylyx Pharmaceuticals has reported positive data from its Phase III LUCIDITY trial for avexitide, an investigational glucagon-like peptide-1 (GLP-1) receptor antagonist, in post-bariatric hypoglycaemia (PBH). The randomized, double-blind, placebo-controlled study enrolled 78 adult patients who developed PBH following Roux-en-Y gastric bypass (RYGB) surgery. Over a 16-week blinded phase, once-daily subcutaneous avexitide significantly reduced the composite rate of self-monitoring of blood glucose-confirmed Level 2 and blinded Event Adjudication Committee-adjudicated Level 3 hypoglycaemic events by 55% compared with placebo, achieving statistical significance. The study also met all prespecified secondary endpoints, including a 63% reduction in Level 2 events and a 47% reduction in Level 3 events.
- The LUCIDITY trial demonstrated that once-daily subcutaneous avexitide significantly reduced the composite rate of self-monitoring of blood glucose-confirmed Level 2 and blinded Event Adjudication Committee-adjudicated Level 3 hypoglycaemic events by 55% compared to placebo over a 16-week blinded phase. The least squares (LS) mean event rate reached 0.55 events per week with avexitide versus 1.24 events per week with placebo, achieving robust statistical significance.
- Beyond the primary composite endpoint, avexitide met all prespecified, multiplicity-controlled secondary event-rate endpoints, showing a 63% reduction in Level 2 events, a 47% reduction in Level 3 events, and a 42% reduction in continuous glucose monitoring-detected Level 2 events. This is particularly significant given the high baseline disease burden among patients, with 68% reporting daily hypoglycaemic symptoms and a notable portion having a history of severe events.
- The safety profile of avexitide was favorable, with treatment-emergent adverse events being primarily mild to moderate, gastrointestinal, and injection-site related. No deaths or treatment-related serious adverse events were reported, nor were there clinically meaningful changes in weight or fasting glucose. Avexitide has previously received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for PBH and hyperinsulinemic hypoglycemia, respectively, highlighting its potential to address an unmet medical need.
The Longstanding Treatment Gap in Post-Bariatric Hypoglycaemia
Current treatment of post-bariatric hypoglycaemia (PBH) remains empirical, with no approved therapy and a limited number of therapeutic options that are often associated with adverse side effects. Resolution of postprandial hypoglycaemia remains a challenge for physicians and patients, requiring individualized management and long-term multidisciplinary follow-up.
Lack of approved and evidence-based options: There is no approved therapy for PBH, characterized by enteroinsular axis overstimulation and hyperinsulinaemic hypoglycaemia. Treatment options are empirical, and use of diazoxide or SGLT2 inhibitors, continuous enteral feeding, or surgical reinterventions including reversal of Roux-en-Y gastric bypass or subtotal pancreatectomy is based on limited evidence or not supported by solid evidence.
Inconsistent efficacy on hypoglycaemia: In a randomised, double-blinded, cross-over, placebo-controlled trial, neither acarbose 50 mg thrice daily nor canagliflozin 300 mg twice daily administered for 4 weeks reduced the percentage of time below range during continuous glucose monitoring (interstitial glucose below 3.9 mM/70 mg/dL). In an experimental crossover study, verapamil 120 mg and liraglutide 1.2 mg had no effect on hypoglycaemia, while sitagliptin 100 mg lowered nadir glucose values.
Tolerability and treatment burden: Acarbose was associated with moderate and common side effects that caused treatment discontinuation in one participant, and gastrointestinal side effects limit continuation of voglibose. Nutritional limitations were difficult to sustain, and patients developed adverse effects to pharmacological therapy with acarbose and subcutaneous octreotide with meals such that doses could not be increased. Two patients dropped out because of adverse gastrointestinal events under pasireotide 300 μg s.c. t.i.d.
Glycaemic trade-offs and cost: Acarbose reduced peak glucose levels and time in hyperglycaemia, whereas pasireotide greatly increased both variables and leads to increased and sustained hyperglycaemia. The most effective therapy is the use of short- or long-acting somatostatin analogues, which is however expensive and entails side effect issues.
Emerging therapies remain investigational: Avexitide, glucagon pump, broad-spectrum somatostatin analogue pasireotide, GLP-1 receptor antagonists, GLP-1 receptor agonists including beinaglutide and tirzepatide, and administration of stable forms of glucagon are currently under study or recently tested, with further studies needed to confirm efficacy and establish optimal dosing strategies.
Unpacking LUCIDITY: Avexitide's Phase 3 Design and Efficacy
Recent randomized and experimental trials in post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass have tested oral agents, peptide antagonists, glucagon analogues and device-guided strategies using mixed-meal tolerance tests (MMTT) and continuous glucose monitoring (CGM). Designs are predominantly randomized, placebo-controlled crossover studies with small sample sizes and short treatment periods. Primary endpoints focus on glucose nadir, time below range and amplitude of glucose excursion.
HypoBar I acarbose vs canagliflozin vs placebo: randomised, double-blinded, cross-over, placebo-controlled trial where placebo, acarbose 50 mg thrice daily, and canagliflozin 300 mg twice daily were administered for 4 weeks in 11 participants with Roux-en-Y gastric bypass and documented PBH, with blinded CGM for 10 days at the end of each intervention; primary outcome was percentage of time below range during CGM (interstitial glucose below 3.9 mM/70 mg/dL), with median (IQR) screening 2.6 (0.7-5.1)%, placebo 1.2 (0.5-2.4)%, acarbose 1.1 (0.8-1.7)% and canagliflozin 0.8 (0.5-3.4)%.
Dasiglucagon outpatient and meal-test trials: randomized, double-blind, placebo-controlled, crossover, proof-of-concept study in 24 individuals with CGM-verified PBH (≥15 min at <3.9 mmol/L three or more times per week) assigned to 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo, with primary and key secondary outcomes of CGM-captured percentage of time in level 1 and 2 hypoglycaemia (<3.9 and <3.0 mmol/L); separate randomized, double-blind, placebo-controlled, crossover trial in 10 RYGB-operated participants with 3 trial days of 240-min standardized liquid mixed-meal test with subcutaneous placebo or 80 μg or 200 μg dasiglucagon, assessing nadir plasma glucose and time in hypoglycaemia (PG <3.9 mmol/L).
Avexitide [exendin (9-39)] Phase 2 programs: multicenter, Phase 2, randomized, placebo-controlled crossover study (PREVENT) in 18 female patients given placebo for 14 days followed by avexitide 30 mg twice daily and 60 mg once daily, each for 14 days in random order, with main outcome measures of glucose nadir and insulin peak during MMTT and hypoglycaemic events by self-monitoring of blood glucose, electronic diary and blinded CGM; phase 2, multiple-ascending-dose study at Stanford University in 19 women with baseline oral glucose tolerance test then 3 days of twice-daily lyophilized avexitide at four ascending-dose levels (n=14) and liquid formulation 30 mg twice daily for 3 days (n=5), with repeat OGTT on day 3 for metabolic, symptomatic and pharmacokinetic responses.
Multi-drug crossover and SGLT inhibitor trials: randomized crossover study in 11 women with documented hypoglycaemia evaluated during baseline without treatment and five periods of acarbose 50 mg for 1 week, sitagliptin 100 mg for 1 week, verapamil 120 mg for 1 week, liraglutide 1.2 mg for 3 weeks and pasireotide 300 μg as single dose, evaluated by MMTT and, except pasireotide, 6 days of CGM; randomized, double-blind, placebo-controlled crossover trial in 22 adults of empagliflozin 25 mg or placebo once daily over 20 days with primary efficacy outcome of amplitude of plasma glucose excursion (peak to nadir) during MMTT and outpatient CGM; phase 2, open-label, randomized, single-dose, crossover study in 9 participants of mizagliflozin 2.5-mg liquid and 2.5-, 5- and 10-mg capsules before MMTTs, with primary outcome change from baseline in glucose nadir and secondary change in peak glucose and peak insulin.
Device, algorithm and peptide pilot studies: open-label study of subcutaneous pramlintide with sequential increase to maximum 120 micrograms (mean 69 ± 32 mcg) three times daily over 8 weeks in 20 dosed participants (14 completed), with MMTT at baseline and 8 weeks and primary endpoint change in glucose excursions during MMTT plus secondary MMTT insulin, satiety and dumping score, percentage time sensor glucose <3.9 mM and days with minimum SG <3 mM during masked CGM; iterative development study in 7 participants with PBH and neuroglycopenia using Dexcom CGM connected to tablet prediction algorithm and Omnipod pump with stable liquid glucagon 150 μg then 300 μg; randomized trial in 59 participants of 5 g glucose upon CGM-guided forecasting alert (n=32) versus when plasma glucose declined below 3.0 mmol/L (n=27); crossover study in 14 patients of unblinded CGM versus blinded CGM/no alarms for 10 days each assessing fingerstick-confirmed events, CGM nadir and Hypoglycemia Fear Survey-II.
Avexitide's Favorable Safety Profile and Clinical Impact
Avexitide 45 mg BID and 90 mg QD was well tolerated in adults with hypoglycemia following Roux-en-Y gastric bypass, sleeve gastrectomy, total gastrectomy, or Nissen fundoplication, with no serious adverse events and no discontinuations due to adverse events. In the PREVENT crossover study in patients with postbariatric hypoglycemia, avexitide 30 mg twice daily and 60 mg once daily administered for 28 days was well tolerated, with no increase in adverse events, and blinded continuous glucose monitoring demonstrated reductions in hypoglycemia without induction of clinically relevant hyperglycemia.
Single ascending subcutaneous doses of exendin 9-39 in women with recurrent symptomatic hypoglycemia after Roux-en-Y gastric bypass were well tolerated with no treatment-emergent adverse events observed. In a multiple-ascending-dose study of twice-daily lyophilized avexitide and a fixed dose of 30 mg twice daily of a novel liquid formulation for 3 days in women with post-bariatric hypoglycaemia, both formulations were well tolerated while raising glucose nadir and preventing severe hypoglycaemia requiring rescue intervention.
Frequently Asked Questions
References
- [1] Deloose E, Bisschops R et al.. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome. Neurogastroenterology and motility. 2014 Jun. 24750284
- [2] Lobato CB, Winding CT et al.. Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial. Diabetes, obesity & metabolism. 2026 May. 41810556
- [3] Turk N, Yandle E et al.. Rapid gastric emptying rate in postbariatric hypoglycemia and effect of glucagon-like peptide-1 receptor agonist on postprandial hypoglycemia. The Journal of clinical endocrinology and metabolism. 2026 Sep 24. 42784533
- [4] Nielsen CK, Øhrstrøm CC et al.. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes care. 2022 Jun 2. 35320361
- [5] De León DD, Li C et al.. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion. The Journal of biological chemistry. 2008 Sep 19. 18635551
- [6] Ferreira A, Schönenberger KA et al.. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes technology & therapeutics. 2023 Jul. 37093196
- [7] Ding B, Hu Y et al.. Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report. Medicine. 2021 May 28. 34032745
- [8] Lobato CB, Winding CT et al.. Canagliflozin or acarbose versus placebo to ameliorate post-bariatric hypoglycaemia - The HypoBar I randomized clinical trial protocol. Diabetic medicine : a journal of the British Diabetic Association. 2024 Jun. 38551152
- [9] Carpentieri GB, Gonçalves SEAB et al.. Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder. Archives of endocrinology and metabolism. 2023 Mar 30. 36748934
- [10] Craig CM, Liu LF et al.. Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia. Diabetes, obesity & metabolism. 2018 Feb. 28776922
- [11] Øhrstrøm CC, Worm D et al.. Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2017 Feb. 27865808
- [12] Turk N, Ramanujan S et al.. Continuous Glucose Monitoring in Patients With Postbariatric Hypoglycemia: Effect on Hypoglycemia and Quality of Life. Journal of the Endocrine Society. 2025 Sep. 40862087
- [13] Kato K, Kageyama S et al.. End-stage Renal Disease in Which Diazoxide Was Effective in Treating Hypoglycemia Caused by Late Dumping Syndrome after Gastrectomy. Internal medicine (Tokyo, Japan). 2024 May 15. 37813619
- [14] Kassem MA, Durda MA et al.. The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus and the Management of Hypoglycemic Events. Frontiers in endocrinology. 2017. 28298900
- [15] Patti ME, Li P et al.. Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypass. Obesity (Silver Spring, Md.). 2015 Apr. 25755084
- [16] Herzig D, Schiavon M et al.. Unraveling, contributing factors to the severity of postprandial hypoglycemia after gastric bypass surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2023 May. 36509672
- [17] van Furth AM, de Heide LJM et al.. Dumping Syndrome and Postbariatric Hypoglycemia: Supporting Evidence for a Common Etiology. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2021 Nov. 34144916
- [18] Wang C, Pang S et al.. Treatment with acarbose in severe hypoglycaemia due to late dumping syndrome. The West Indian medical journal. 2013 Dec. 25117397
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com










